SCHEMBL6090163

SCHEMBL6090163

O=C(Nc1c(C(=O)O)n(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c2cc(-c3ccc4c(c3)OOC4)ccc12)c1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 3/20 0.41
EGLN2 Q96KS0 1/20 0.36
EGLN1 Q9GZT9 1/20 0.36
EGLN3 Q9H6Z9 1/20 0.36
SLC2A1 P11166 1/20 0.35
PTGER4 P35408 1/20 0.35
ENPP2 Q13822 1/20 0.35
HDAC1 Q13547 2/20 0.34
HDAC8 Q9BY41 2/20 0.34
HDAC6 Q9UBN7 2/20 0.34
CTNNB1 P35222 3/20 0.34
TCF7L2 Q9NQB0 3/20 0.34
STAT3 P40763 1/20 0.34
STAT1 P42224 1/20 0.34
ACLY P53396 1/20 0.34
RHOC P08134 3/20 0.33
RHOA P61586 3/20 0.33
XPO1 O14980 1/20 0.33
HDAC11 Q96DB2 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6090166 0.87 EDNRA (0.47) ABCB1MAPT
SCHEMBL6091451 0.79 SLC2A1 (0.44) ABCB1EGLN2EGLN1EGLN3SLC2A1
SCHEMBL6090836 0.76 PPARG (0.47) ABCB1EGLN2EGLN1EGLN3PTGER4
SCHEMBL6091368 0.73 GRIN1 (0.43) EGLN2EGLN1EGLN3SLC2A1PTGER4
SCHEMBL6093040 0.72 SERPINE1 (0.45) ABCB1SLC2A1
SCHEMBL6089976 0.72 PTGES (0.44) ABCB1SLC2A1PTGER4MAPT
SCHEMBL5749488 0.72 PTGER4 (0.46) ABCB1SLC2A1PTGER4HDAC1HDAC8
SCHEMBL6092421 0.71 PTGES (0.57) ABCB1SLC2A1PTGER4
SCHEMBL6093252 0.71 GRIN1 (0.45) ABCB1SLC2A1PTGER4HDAC1HDAC8
SCHEMBL5748986 0.70 PTGER4 (0.42) ABCB1SLC2A1PTGER4HDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160879-A1 Indoles useful in the treatment of inflammation BIOLIPOX AB (SE) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160879-A1 Indoles useful in the treatment of inflammation IDO1, PTGS1, IDO2 ABCB1 1475/4885EGLN2 529/4885EGLN1 825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.